IXO THERAPEUTICS LTD.
IXO Therapeutics Ltd. is a biotechnology company formed to research and develop novel medicines from natural sources for the treatment of immune-mediated and inflammatory diseases.
IXO THERAPEUTICS LTD.
Industry:
Biotechnology Medical
Founded:
2010-01-01
Address:
Swindon, Wiltshire, United Kingdom
Country:
United Kingdom
Status:
Active
Contact:
+44 (0) 7748357352
Total Funding:
0
Similar Organizations
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Investors List
Oxford University Innovation
Oxford University Innovation investment in Seed Round - IXO Therapeutics Ltd.
More informations about "IXO Therapeutics Ltd."
IXO Therapeutics Ltd. - Funding, Financials, Valuation & Investors
IXO Therapeutics Ltd. is a biotechnology company researching and developing novel immunotherapeuticsSee details»
IXO Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials
Explore IXO Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, , Drug:IXO-702, IXO-423, IXO-602.See details»
IXO Therapeutics - Products, Competitors, Financials, Employees ...
IXO Therapeutics is a biotechnology company formed to research and develop novel medicines from natural sources for the treatment of immune-mediated and inflammatory diseases. Use …See details»
IXO THERAPEUTICS LIMITED - Companies House
IXO THERAPEUTICS LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business …See details»
Isis Participates in New Start-up Company Developing Novel …
13th December 2010. Oxford University Innovation Ltd, the technology transfer company of the University of Oxford, is pleased to announce its participation in the formation of IXO …See details»
IXO Therapeutics Ltd. - Crunchbase
IXO Therapeutics Ltd. is a biotechnology company researching and developing novel immunotherapeuticsSee details»
IXO THERAPEUTICS LIMITED overview - Companies House
Apr 17, 2018 More for IXO THERAPEUTICS LIMITED (06106043) Registered office address James Cowper Llp, 2 Chawley Park, Cumnor Hill, Oxford, OX2 9GG . Company status …See details»
IXO Therapeutics - VentureRadar
Similar Companies: Pathios Therapeutics United Kingdom Privately Held Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced …See details»
Isis participates in new start-up company developing novel …
There is a significant opportunity for IXO Therapeutics to deliver both medicinal and economic value to the UK as the company develops its products.” Tom Hockaday, Managing director of …See details»
New biotech firm IXO Therapeutics to develop autoimmune …
IXO Therapeutics is a start-up from the Natural Environment Research Council (NERC) and will focus on developing intellectual property (IP) derived from both NERC and the University of …See details»
IXO Therapeutics - CB Insights
Nov 1, 2010 See IXO Therapeutics funding rounds, investors, investments, exits and more. Evaluate their financials based on IXO Therapeutics's post-money valuation and revenue. IXO …See details»
IXO-602 - Drug Targets, Indications, Patents - Synapse - Patsnap
IXO-602: a IgE inhibitors Drug, Initially developed by IXO Therapeutics Ltd., Now, its global highest R&D status is Discontinued, Mechanism: IgE inhibitors ...See details»
IXO-423 - Drug Targets, Indications, Patents - Synapse - Patsnap
BACKGROUND Bacterial contamination of platelet products is the major infectious risk in blood transfusion medicine, which can result in life-threatening sepsis in recipient. Lipocalin 2 (Lcn2) …See details»
Exploring new horizons in neovascular age-related macular
Oct 8, 2024 Emerging therapeutics aim to reduce vision-loss through a variety of mechanisms. Gene therapies, including RGX-314 and Ixo-vec, express an anti-VEGF protein, and 4D-150, …See details»
Novel Immunomodulators from Hard Ticks Selectively …
Oxford, and were licenced to IXO Therapeutics Ltd. until 31st Dec 2012; the licence has now expired and there are currently no commercial activities relating to these patents. SGP, CK, …See details»
Congruence and Ono Announce Multi-Target Research ... - Newswire
2 days ago OSAKA, Japan and MONTREAL, Dec. 3, 2024 /CNW/ -- Congruence Therapeutics today announced that it has entered into a research collaboration agreement with Ono …See details»
IXO-702 - Drug Targets, Indications, Patents - Synapse - Patsnap
IXO-702: a LTB4R antagonists, Lipocalin modulators Drug, Initially developed by IXO Therapeutics Ltd., Now, its global highest R&D status is Discontinued, Mechanism ...See details»
IXO Therapeutics - VentureRadar
Pathios Therapeutics United Kingdom Privately Held Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced pharmaceutical …See details»
Safety and efficacy of ixoberogene soroparvovec in neovascular …
Ixo-vec was generally well-tolerated, maintained vision, and improved anatomical outcomes in nAMD, with a substantial reduction in anti-VEGF injections. A single administration of an in …See details»
IXO-423 - Drug Targets, Indications, Patents - Synapse
Last update 02 Apr 2024. IXO-423. Last update 02 Apr 2024See details»